NanoView: Driving a Better Understanding of Extracellular Vesicles (EVs)
An exponentially growing body of research has indicated that exosomes are involved in cellular communication and a better understanding of their function may have a significant impact on diseases like cancer, neurodegenerative disorders, and cardiovascular disease. Given their circulation in all biological fluids, exosome-based liquid biopsies are being investigated for early disease detection and treatment. Exosomes are also being studied as next generation therapeutics due to their long half-lives in vivo and capacity to deliver therapeutic cargo inside cells.
NanoView Biosciences, founded in 2015 based on research based at Boston University, manufactures and sells products and services which enable researchers in life science to better understand the biology of extracellular vesicles (EVs) including exosomes. NanoView's mission is to facilitate the translation of extracellular vesicles (EVs) including exosomes for life science research to clinical diagnostics and therapeutics by providing proprietary, high-throughput, cost-effective analysis solutions.
NanoView’s proprietary ExoView® products include the ExoView R100 automated microscope, dedicated ExoView Kits, and ExoViewer Software. ExoView is designed to specifically detect and fully characterize exosomes for use in basic, translational and clinical research, enabling the development of diagnostic and therapeutic products for nanomedicine. ExoView is a high-throughput, cost-effective analysis system that is easy to use and does not require purification or large sample volumes. This innovative platform is able to determine the size of EVs down to 50nm, detect single fluorescence molecules, and characterize up to 4 biomarkers simultaneously found on the surface and inside of exosomes. ExoView was launched in February 2019 at the Society of Laboratory Automation and Screening International Conference (SLAS) where it was awarded Best New Product.
NanoView segments its target markets by application of its core technology. ExoView was initially launched into the Research Use Only (RUO) life science instrumentation market. The worldwide life science instrumentation market estimate was $21.7B in 2019 (Strategic Directions International 2019). As an estimate of the “early adopter” market for exosome characterization, NanoView aligns with the International Society for Extracellular Vesicles (ISEV) and its membership of over 1,000 EV researchers. As the use of exosomes for biomarker discovery expands into diagnostic and therapeutic development, NanoView anticipates its target markets will widen. Allied Market Research reported the 2018 global biomarker technologies market at $21.6B with a 5-year CAGR of 13.2%. Finally, exosomes have been characterized for both liquid biopsy and companion diagnostic applications. Both of these specific application areas require significant further development; however, the payout is sizeable. Allied Market Research projects the global liquid biopsy market to reach $6.5B by 2026 with a CAGR of 18.3% and estimates that the global companion diagnostic market will reach $6.5B by 2023 with a 5-year CAGR of 20.1%.